- Home
- UYSC vs SNTI Comparison
UYSC vs SNTI Comparison
Compare UYSC & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UYSC
- SNTI
- Stock Information
- Founded
- UYSC 2024
- SNTI 2016
- Country
- UYSC United States
- SNTI United States
- Employees
- UYSC N/A
- SNTI N/A
- Industry
- UYSC Blank Checks
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- UYSC Finance
- SNTI Health Care
- Exchange
- UYSC Nasdaq
- SNTI Nasdaq
- Market Cap
- UYSC 76.5M
- SNTI 85.3M
- IPO Year
- UYSC 2025
- SNTI N/A
- Fundamental
- Price
- UYSC $10.05
- SNTI $2.22
- Analyst Decision
- UYSC
- SNTI Strong Buy
- Analyst Count
- UYSC 0
- SNTI 2
- Target Price
- UYSC N/A
- SNTI $8.50
- AVG Volume (30 Days)
- UYSC 8.5K
- SNTI 369.7K
- Earning Date
- UYSC 01-01-0001
- SNTI 08-12-2025
- Dividend Yield
- UYSC N/A
- SNTI N/A
- EPS Growth
- UYSC N/A
- SNTI N/A
- EPS
- UYSC N/A
- SNTI N/A
- Revenue
- UYSC N/A
- SNTI N/A
- Revenue This Year
- UYSC N/A
- SNTI N/A
- Revenue Next Year
- UYSC N/A
- SNTI $150.00
- P/E Ratio
- UYSC N/A
- SNTI N/A
- Revenue Growth
- UYSC N/A
- SNTI N/A
- 52 Week Low
- UYSC $10.00
- SNTI $1.52
- 52 Week High
- UYSC $11.00
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- UYSC N/A
- SNTI 36.43
- Support Level
- UYSC N/A
- SNTI $1.90
- Resistance Level
- UYSC N/A
- SNTI $2.22
- Average True Range (ATR)
- UYSC 0.00
- SNTI 0.32
- MACD
- UYSC 0.00
- SNTI -0.03
- Stochastic Oscillator
- UYSC 0.00
- SNTI 17.33
About UYSC UY Scuti Acquisition Corp. Ordinary Shares
UY Scuti Acquisition Corp is a newly organized blank check company.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.